➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Colorcon
AstraZeneca
Baxter
Merck
Dow

Last Updated: July 13, 2020

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 208447


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

NDA 208447 describes ZEJULA, which is a drug marketed by Glaxosmithkline and is included in one NDA. It is available from one supplier. There are five patents protecting this drug. Additional details are available on the ZEJULA profile page.

The generic ingredient in ZEJULA is niraparib tosylate. One supplier is listed for this compound. Additional details are available on the niraparib tosylate profile page.
Summary for 208447
Tradename:ZEJULA
Applicant:Glaxosmithkline
Ingredient:niraparib tosylate
Patents:5
Generic Entry Opportunity Date for 208447
Generic Entry Date for 208447*:
Constraining patent/regulatory exclusivity:
Dosage:
CAPSULE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for NDA: 208447
Suppliers and Packaging for NDA: 208447
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ZEJULA niraparib tosylate CAPSULE;ORAL 208447 NDA GlaxoSmithKline LLC 69656-103 69656-103-30 30 CAPSULE in 1 BOTTLE (69656-103-30)
ZEJULA niraparib tosylate CAPSULE;ORAL 208447 NDA GlaxoSmithKline LLC 69656-103 69656-103-61 30 CAPSULE in 1 BOTTLE (69656-103-61)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrengthEQ 100MG BASE
Approval Date:Mar 27, 2017TE:RLD:Yes
Regulatory Exclusivity Expiration:Mar 27, 2024
Regulatory Exclusivity Use:INDICATED FOR MAINTENANCE TREATMENT OF ADULT PATIENTS WITH RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO PLATINUM-BASED CHEMOTHERAPY
Regulatory Exclusivity Expiration:Mar 27, 2022
Regulatory Exclusivity Use:NEW CHEMICAL ENTITY
Regulatory Exclusivity Expiration:Oct 23, 2022
Regulatory Exclusivity Use:TX OF ADULT PTS W/ ADV OVARIAN FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER TREATED W/ >=3 PRIOR CHEMO REGIMENS & ASSOCIATED W/ HRD DEFICIENCY POSITIVE STATUS DEFINED BY A DELETERIOUS OR SUSPECTED DELETERIOUS BRCA MUTATION

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts
Moodys
McKesson
AstraZeneca
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.